SE526711C2 - Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav - Google Patents

Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav

Info

Publication number
SE526711C2
SE526711C2 SE0300245A SE0300245A SE526711C2 SE 526711 C2 SE526711 C2 SE 526711C2 SE 0300245 A SE0300245 A SE 0300245A SE 0300245 A SE0300245 A SE 0300245A SE 526711 C2 SE526711 C2 SE 526711C2
Authority
SE
Sweden
Prior art keywords
cure
strains
bifidobacterium
dsm
strain
Prior art date
Application number
SE0300245A
Other languages
English (en)
Swedish (sv)
Other versions
SE0300245L (sv
SE0300245D0 (sv
Inventor
Goeran Molin
Siv Ahrne
Bengt Jeppsson
Original Assignee
Probi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi Ab filed Critical Probi Ab
Priority to SE0300245A priority Critical patent/SE526711C2/sv
Publication of SE0300245D0 publication Critical patent/SE0300245D0/xx
Priority to BRPI0407176A priority patent/BRPI0407176B8/pt
Priority to ZA200505777A priority patent/ZA200505777B/en
Priority to CA2514659A priority patent/CA2514659C/en
Priority to JP2006502776A priority patent/JP4540664B2/ja
Priority to PCT/SE2004/000098 priority patent/WO2004067731A1/en
Priority to AU2004208084A priority patent/AU2004208084B2/en
Priority to AT04705562T priority patent/ATE496115T1/de
Priority to EP04705562A priority patent/EP1587913B1/en
Priority to DE602004031079T priority patent/DE602004031079D1/de
Priority to RU2005127331/13A priority patent/RU2352628C2/ru
Priority to PL378435A priority patent/PL212096B1/pl
Priority to CNB2004800088252A priority patent/CN100558883C/zh
Priority to US10/543,604 priority patent/US7947482B2/en
Priority to DK04705562.9T priority patent/DK1587913T3/da
Priority to ES04705562T priority patent/ES2362496T3/es
Publication of SE0300245L publication Critical patent/SE0300245L/xx
Publication of SE526711C2 publication Critical patent/SE526711C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A23L1/3014—
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C12R1/01—
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/529—Infantis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
SE0300245A 2003-01-31 2003-01-31 Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav SE526711C2 (sv)

Priority Applications (16)

Application Number Priority Date Filing Date Title
SE0300245A SE526711C2 (sv) 2003-01-31 2003-01-31 Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
ES04705562T ES2362496T3 (es) 2003-01-31 2004-01-27 Nuevas cepas de bifidobacterium que tienen la capacidad para producir glutamina.
EP04705562A EP1587913B1 (en) 2003-01-31 2004-01-27 New strains of bifidobacterium having the ability to produce glutamine
RU2005127331/13A RU2352628C2 (ru) 2003-01-31 2004-01-27 Новые штаммы бифидобактерий, обладающие способностью продуцировать глутамин
CA2514659A CA2514659C (en) 2003-01-31 2004-01-27 New strains of bifidobacterium having the ability to produce glutamine
JP2006502776A JP4540664B2 (ja) 2003-01-31 2004-01-27 グルタミン産生能を有する新規のＢｉｆｉｄｏｂａｃｔｅｒｉｕｍ菌株
PCT/SE2004/000098 WO2004067731A1 (en) 2003-01-31 2004-01-27 New strains of bifidobacterium having the ability to produce glutamine
AU2004208084A AU2004208084B2 (en) 2003-01-31 2004-01-27 New strains of Bifidobacterium having the ability to produce glutamine
AT04705562T ATE496115T1 (de) 2003-01-31 2004-01-27 Neue bifidobacterium-stämme mit der fähigkeit zur herstellung von glutamin
BRPI0407176A BRPI0407176B8 (pt) 2003-01-31 2004-01-27 composições compreendendo uma ou mais cepas de bifidobacterium e seus usos
DE602004031079T DE602004031079D1 (de) 2003-01-31 2004-01-27 Neue bifidobacterium-stämme mit der fähigkeit zur herstellung von glutamin
ZA200505777A ZA200505777B (en) 2003-01-31 2004-01-27 New strains of bifidobacterium having the ability to produce glutamine
PL378435A PL212096B1 (pl) 2003-01-31 2004-01-27 Wyizolowane szczepy Bifidobacterium infantis i środek farmaceutyczny
CNB2004800088252A CN100558883C (zh) 2003-01-31 2004-01-27 具有产生谷氨酰胺的能力的双歧杆菌属的新菌株
US10/543,604 US7947482B2 (en) 2003-01-31 2004-01-27 Strains of bifidobacterium having the ability to produce glutamine
DK04705562.9T DK1587913T3 (da) 2003-01-31 2004-01-27 Nye stammer af Bifidobacterium, som har evnen til at producere glutamin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0300245A SE526711C2 (sv) 2003-01-31 2003-01-31 Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav

Publications (3)

Publication Number Publication Date
SE0300245D0 SE0300245D0 (sv) 2003-01-31
SE0300245L SE0300245L (sv) 2004-08-01
SE526711C2 true SE526711C2 (sv) 2005-10-25

Family

ID=20290264

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0300245A SE526711C2 (sv) 2003-01-31 2003-01-31 Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav

Country Status (16)

Country Link
US (1) US7947482B2 (enExample)
EP (1) EP1587913B1 (enExample)
JP (1) JP4540664B2 (enExample)
CN (1) CN100558883C (enExample)
AT (1) ATE496115T1 (enExample)
AU (1) AU2004208084B2 (enExample)
BR (1) BRPI0407176B8 (enExample)
CA (1) CA2514659C (enExample)
DE (1) DE602004031079D1 (enExample)
DK (1) DK1587913T3 (enExample)
ES (1) ES2362496T3 (enExample)
PL (1) PL212096B1 (enExample)
RU (1) RU2352628C2 (enExample)
SE (1) SE526711C2 (enExample)
WO (1) WO2004067731A1 (enExample)
ZA (1) ZA200505777B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012048438A1 (es) 2010-10-14 2012-04-19 Universidad De Concepcion Alimento funcional probiótico adecuado para individuos inmunocomprometidos sometidos a tratamientos como quimioterapia y/o radioterapia
RU2699967C1 (ru) * 2018-12-25 2019-09-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ комплексного лечения энтеральной недостаточности у детей с тяжелой термической травмой

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2277524B1 (en) 2005-09-28 2015-11-11 Nordisk Rebalance A/S Treatment of IBS using both probiotic bacteria and fermented cereal as treatment effectors
AU2006297896B2 (en) * 2005-10-06 2011-12-08 Probi Ab Use of lactobacillus for treatment of autoimmune diseases
JP5837879B2 (ja) * 2010-07-05 2015-12-24 株式会社明治 腸内腐敗物質の低減作用を有するビフィズス菌
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
CN103131647B (zh) * 2011-11-29 2017-06-27 上海上药信谊药厂有限公司 婴儿双歧杆菌及其制剂
CN110201003A (zh) 2012-02-29 2019-09-06 伊西康内外科公司 微生物区系的组合物及与其相关的方法
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
CN113730442A (zh) 2014-10-31 2021-12-03 潘德勒姆治疗公司 与病症的微生物治疗和诊断有关的方法和组合物
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
CN108330166A (zh) * 2017-09-06 2018-07-27 深圳市百澳飞生物技术有限公司 一种酶制剂的饲用活性评估方法
AU2019306649A1 (en) 2018-07-19 2021-02-04 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
US11045507B2 (en) 2019-02-21 2021-06-29 Ewelina Sosnowska-Turek Bifidobacterium animalis AMT30 strain and the composition containing the strain of Bifidobacterium animalis AMT30

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59155321A (ja) * 1983-02-25 1984-09-04 Riyoushiyoku Kenkyukai 整腸用製剤
DE3406772A1 (de) * 1984-02-24 1986-03-13 Angelo 8137 Berg Schuler Diaetetisches mittel zur herabsetzung der harnstoffkonzentration in koerperfluessigkeiten und seine herstellung
SE9002732D0 (sv) * 1990-08-24 1990-08-24 Kabivitrum Ab Product containing growth factor
IT1254210B (it) * 1992-02-10 1995-09-14 Simone Claudio De Composizioni dietetiche e/o farmaceutiche a base di batteri lattici liofilizzati, loro preparazione e impiego
JP3623977B2 (ja) * 1993-10-29 2005-02-23 明治乳業株式会社 潰瘍性大腸炎治療剤
JP4852681B2 (ja) * 1996-02-28 2012-01-11 雪印メグミルク株式会社 腸管内細胞溶解活性抑制剤
IT1288119B1 (it) * 1996-06-28 1998-09-10 Renata Maria Anna Ve Cavaliere Composizioni dietetiche da utilizzare nell'alimentazione per via enterica
RU2112034C1 (ru) * 1996-12-26 1998-05-27 Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского Штамм bifidobacterium infantis 73-15, используемый для приготовления бифидосодержащих бактерийных препаратов и продуктов лечебно-диетического питания
CN1099289C (zh) * 1997-08-01 2003-01-22 北京东方百信生物技术有限公司 改善肠道生态平衡的微生物制剂及其工艺
US6203797B1 (en) * 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US6926891B1 (en) * 1999-08-05 2005-08-09 Nestec S.A. Treatment of diarrhea with strains of Bifidobacterium longum
US6468525B1 (en) * 1999-08-10 2002-10-22 Renew Life, Inc. Probiotic formulation
WO2001083700A2 (en) 2000-05-03 2001-11-08 University Of Maryland, Baltimore Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal
AU2001265253A1 (en) * 2000-07-07 2002-01-21 First Circle Medical, Inc. Treatment of hiv using hyperthermia
JP2002186422A (ja) * 2000-12-22 2002-07-02 Morinaga Milk Ind Co Ltd ラクトバシラス・ガッセリ及びビフィドバクテリウム属の菌を含有する非発酵食品
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
PL367083A1 (en) * 2001-02-06 2005-02-21 Societe Des Produits Nestle S.A. Endotoxin binding by lactic acid bacteria and bifidobacteria
US20030017192A1 (en) * 2001-06-19 2003-01-23 Hanny Kanafani Process for producing extended shelf-life ready-to-use milk compositions containing probiotics
US20030092163A1 (en) * 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
JP3364491B2 (ja) * 2002-07-25 2003-01-08 株式会社アトリエ・ド・フロマージュ ヨーグルトおよびその製造方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012048438A1 (es) 2010-10-14 2012-04-19 Universidad De Concepcion Alimento funcional probiótico adecuado para individuos inmunocomprometidos sometidos a tratamientos como quimioterapia y/o radioterapia
RU2699967C1 (ru) * 2018-12-25 2019-09-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ комплексного лечения энтеральной недостаточности у детей с тяжелой термической травмой

Also Published As

Publication number Publication date
AU2004208084B2 (en) 2008-10-09
JP2006516405A (ja) 2006-07-06
PL378435A1 (pl) 2006-04-03
US7947482B2 (en) 2011-05-24
BRPI0407176B8 (pt) 2021-05-25
BRPI0407176A (pt) 2006-02-07
EP1587913B1 (en) 2011-01-19
SE0300245L (sv) 2004-08-01
PL212096B1 (pl) 2012-08-31
EP1587913A1 (en) 2005-10-26
JP4540664B2 (ja) 2010-09-08
CA2514659C (en) 2014-07-08
CN1777670A (zh) 2006-05-24
CN100558883C (zh) 2009-11-11
SE0300245D0 (sv) 2003-01-31
US20060269533A1 (en) 2006-11-30
ES2362496T3 (es) 2011-07-06
AU2004208084A1 (en) 2004-08-12
DE602004031079D1 (de) 2011-03-03
DK1587913T3 (da) 2011-04-11
RU2005127331A (ru) 2006-01-27
ZA200505777B (en) 2007-12-27
RU2352628C2 (ru) 2009-04-20
ATE496115T1 (de) 2011-02-15
BRPI0407176B1 (pt) 2018-05-08
CA2514659A1 (en) 2004-08-12
WO2004067731A1 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
CN114480229B (zh) 一种动物双歧杆菌乳亚种菌株wkb148及其产品与应用
CN112175864B (zh) 动物双歧杆菌及其选育方法和应用
EP0760848A1 (en) Lactobacillus strains of human origin, their compositions and uses thereof
EP2179028A1 (en) A novel strain of bifidobacterium and active peptides against rotavirus infections
CN110373368B (zh) 一种长双歧杆菌菌株zj1及其应用
SE526711C2 (sv) Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
CN113832077A (zh) 鼠李糖乳杆菌及其应用
CN114774315A (zh) 鼠李糖乳杆菌菌株LRa05在制备增强免疫力制品和/或缓解湿疹制品方面的用途
CN117866831A (zh) 一种鼠李糖乳酪杆菌及其应用
CN114990030B (zh) 嗜酸乳杆菌la18及其在制备调节肠道菌群或免疫调节的产品方面的应用
CN117004538A (zh) 一种罗伊氏粘液乳杆菌及应用
CN110023484B (zh) 一种假小链状双歧杆菌及其培养方法和应用
CN106906165A (zh) 一种植物乳杆菌及其在制备预防便秘的食品中的应用
Pieniz et al. Evaluation of selenite bioremoval from liquid culture by Enterococcus species
Park et al. Safety assessment of Lactobacillus fermentum PL9005, a potential probiotic lactic acid bacterium, in mice
CN104053766A (zh) 产生罗伊氏菌素的短乳杆菌
CN114574405B (zh) 植物乳杆菌菌株wka86及其在制备防治口臭制品方面的用途与制品
CN111849827B (zh) 犬源产维生素b12乳酸菌及应用
CN116333913A (zh) 一种唾液乳杆菌、含有其的益生菌组合物及其应用
OBISESAN Characterisation of lactic acid bacteria isolated from human breast milk and infant faeces as potential probiotics
CN119639611B (zh) 一种抗隐孢子虫合生元制剂及其制备方法和应用
RU2491332C1 (ru) Консорциум бифидобактерий для приготовления бактерийных препаратов и биологически активных добавок к пище, предназначенных для коррекции микрофлоры желудочно-кишечного тракта людей старше 14 лет, и способ его получения, биологически активная добавка к пище для коррекции микрофлоры желудочно-кишечного тракта людей старше 14 лет и бактериальный препарат для лечения дисбиотических состояний желудочно-кишечного тракта людей старше 14 лет

Legal Events

Date Code Title Description
NUG Patent has lapsed